Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.77 |
| ▸ | MAPT | P10636 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | STAT1 | P42224 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1733506 | 0.94 | DHODH (0.68) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL15936570 | 0.94 | DHODH (0.68) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL12285267 | 0.94 | DHODH (0.68) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL18854079 | 0.92 | DHODH (0.67) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL10863692 | 0.91 | DHODH (0.90) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL10861116 | 0.91 | DHODH (0.78) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL24202615 | 0.90 | DHODH (0.67) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL29254508 | 0.90 | DHODH (0.64) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL10498840 | 0.88 | DHODH (0.62) | DHODHMAPTGAATDP1NPSR1 | |
| SCHEMBL14188926 | 0.88 | DHODH (0.62) | DHODHMAPTGAATDP1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 485 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMACEUTICALS INCORPORATED | 2026-04-23 | — | — | US | disclosed |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | VERTEX PHARMA (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4218754-B1 | VANZACAFTOR FOR USE IN THE TREATMENT OF CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | VERTEX PHARMA (US) | 2026-02-05 | — | — | US | disclosed |
| EP-3634402-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-3697774-B1 | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS | VERTEX PHARMA (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| US-12350262-B2 | Methods of treatment for cystic fibrosis | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-07-08 | — | — | US | disclosed |
| EP-3880197-B9 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4565212-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-0684942-B1 | METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | HOECHST CELANESE CORP (US) | 1998-06-10 | — | — | EP | disclosed |
| US-5488111-A | 8-sulfo-3-quinoline carboxylic acid compounds | HOECHST CELANESE CORPORATION (US) | 1996-01-30 | — | — | US | disclosed |
| EP-0684942-A4 | — | — | 1995-12-27 | — | — | EP | disclosed |
| EP-0684942-A1 | METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | HOECHST CELANESE CORPORATION (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5466808-A | 8-sulfo-3-quinoline carboxylic acids and process therefore | HOECHST CELANESE CORPORATION (US) | 1995-11-14 | — | — | US | disclosed |
| US-5430152-A | Heating aminoarylester in presence of chlorosulfonic acid, oleum | HOECHST CELANESE CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| WO-1994019312-A1 | METHOD FOR PREPARING QUINOLINE CARBOXYLIC ACIDS AND DERIVATIVES THEREOF | HOECHST CELANESE CORPORATION (US) | 1994-09-01 | — | — | WO | disclosed |
| EP-0376870-A1 | A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1990-07-04 | — | — | EP | disclosed |
| EP-0174832-A2 | Ethene derivatives | MAY & BAKER LIMITED (GB) | 1986-03-19 | — | — | EP | disclosed |
| US-4312870-A | TRANQUILIZERS, ANTIDEPRESSANTS | CIBA-GEIGY CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12350262-B2 | Methods of treatment for cystic fibrosis | CFTR, SLC26A4, SCNN1B | DHODH 2962/4885MAPT 4775/4885GAA 208/4885 |
| US-20260108506-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, CLCN2, SCNN1B | DHODH 4438/4885MAPT 4848/4885GAA 2282/4885 |
| US-12384762-B2 | Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator | CFTR, SLC26A4, TMEM109 | DHODH 2013/4885MAPT 4881/4885GAA 1451/4885 |
| US-20260092047-A1 | MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR | CFTR, SLC26A3, SLC26A4 | DHODH 3487/4885MAPT 4868/4885GAA 1461/4885 |
| US-20260034064-A1 | COMPOSITIONS FOR THE TREATMENT OF CFTR-MEDIATED DISEASES | CFTR, ABCC2, ABCC8 | DHODH 2979/4885MAPT 3994/4885GAA 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.